Open AccessSpironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial
Author(s) -
João Pedro Ferreira,
Timothy Collier,
Andrew L. Clark,
Mamas A. Mamas,
HansPeter BrunnerLa Rocca,
Stéphane Heymans,
Arantxa González,
Fozia Ahmed,
Johannes Petutschnigg,
Blerim Mujaj,
Joe Cuthbert,
Philippe Rouet,
Pierpaolo Pellicori,
Beatrice Mariottoni,
Franco Cosmi,
Frank Edelmann,
Lutgarde Thijs,
Jan A. Staessen,
Mark R. Hazebroek,
Job A.J. Verdonschot,
Patrick Rossignol,
Nicolas Girerd,
John G.F. Cleland,
Faı̈ez Zannad
Publication year - 2021
Publication title -
european heart journal - cardiovascular pharmacotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.895
H-Index - 26
eISSN - 2055-6845
pISSN - 2055-6837
DOI - 10.1093/ehjcvp/pvab031
Subject(s) - spironolactone , blood pressure , heart failure , medicine , cardiology
Uncontrolled blood pressure (BP) increases the risk of developing heart failure (HF). The effect of spironolactone on BP of patients at risk of developing HF is yet to be determined. To evaluate the effect of spironolactone on the BP of patients at risk for HF and whether renin can predict spironolactone's effect.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom